https://www.selleckchem.com/products/SNS-032.html
Twelve (66.6%) eyes either improved or maintained BCVA. Mean (±standard deviation [SD]) CMT at baseline and 12 months were 188.2 ± 61.1 μ and 161.7 ± 47.4 μ ( = 0.15), respectively. PED height improved to 236.4 ± 208.7 μ at 12 months ( = 0.05). The mean (±SD) number of injections was 3.28 ± 1.96 with a treatment-free period of 6.83 ± 3.63 months. Three eyes required vPDT (4 treatment sessions; mean 1.33) as a rescue therapy through 12 months. PRN anti-VEGF monotherapy in real-life situations for the treatment of naïve PCV eyes with good
Aimer
Commentaire
Partagez
